全文获取类型
收费全文 | 37052篇 |
免费 | 3307篇 |
国内免费 | 132篇 |
专业分类
耳鼻咽喉 | 438篇 |
儿科学 | 1022篇 |
妇产科学 | 751篇 |
基础医学 | 4486篇 |
口腔科学 | 890篇 |
临床医学 | 4356篇 |
内科学 | 7407篇 |
皮肤病学 | 614篇 |
神经病学 | 3455篇 |
特种医学 | 1147篇 |
外国民族医学 | 5篇 |
外科学 | 5696篇 |
综合类 | 870篇 |
一般理论 | 35篇 |
预防医学 | 3254篇 |
眼科学 | 865篇 |
药学 | 2660篇 |
中国医学 | 44篇 |
肿瘤学 | 2496篇 |
出版年
2021年 | 571篇 |
2020年 | 354篇 |
2019年 | 566篇 |
2018年 | 642篇 |
2017年 | 501篇 |
2016年 | 490篇 |
2015年 | 628篇 |
2014年 | 857篇 |
2013年 | 1330篇 |
2012年 | 1900篇 |
2011年 | 1907篇 |
2010年 | 1124篇 |
2009年 | 1044篇 |
2008年 | 1764篇 |
2007年 | 1952篇 |
2006年 | 1951篇 |
2005年 | 1896篇 |
2004年 | 1808篇 |
2003年 | 1707篇 |
2002年 | 1710篇 |
2001年 | 860篇 |
2000年 | 829篇 |
1999年 | 797篇 |
1998年 | 447篇 |
1997年 | 378篇 |
1996年 | 404篇 |
1995年 | 356篇 |
1994年 | 328篇 |
1993年 | 295篇 |
1992年 | 562篇 |
1991年 | 523篇 |
1990年 | 553篇 |
1989年 | 457篇 |
1988年 | 484篇 |
1987年 | 462篇 |
1986年 | 459篇 |
1985年 | 453篇 |
1984年 | 406篇 |
1983年 | 373篇 |
1982年 | 316篇 |
1981年 | 326篇 |
1980年 | 315篇 |
1979年 | 389篇 |
1978年 | 282篇 |
1977年 | 248篇 |
1976年 | 251篇 |
1975年 | 220篇 |
1974年 | 263篇 |
1973年 | 241篇 |
1972年 | 231篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
3.
4.
Weiyu Ye Anna Olsson-Brown Robert A. Watson Vincent T. F. Cheung Robert D. Morgan Isar Nassiri Rosalin Cooper Chelsea A. Taylor Umair Akbani Oliver Brain Rubeta N. Matin Nicholas Coupe Mark R. Middleton Mark Coles Joseph J. Sacco Miranda J. Payne Benjamin P. Fairfax 《British journal of cancer》2021,124(10):1661
Background Immune checkpoint blockers (ICBs) activate CD8+ T cells, eliciting both anti-cancer activity and immune-related adverse events (irAEs). The relationship of irAEs with baseline parameters and clinical outcome is unclear.Methods Retrospective evaluation of irAEs on survival was performed across primary (N = 144) and secondary (N = 211) independent cohorts of patients with metastatic melanoma receiving single agent (pembrolizumab/nivolumab—sICB) or combination (nivolumab and ipilimumab—cICB) checkpoint blockade. RNA from pre-treatment and post-treatment CD8+ T cells was sequenced and differential gene expression according to irAE development assessed.Results 58.3% of patients developed early irAEs and this was associated with longer progression-free (PFS) and overall survival (OS) across both cohorts (log-rank test, OS: P < 0.0001). Median survival for patients without irAEs was 16.6 months (95% CI: 10.9–33.4) versus not-reached (P = 2.8 × 10−6). Pre-treatment monocyte and neutrophil counts, but not BMI, were additional predictors of clinical outcome. Differential expression of numerous gene pathway members was observed in CD8+ T cells according to irAE development, and patients not developing irAEs demonstrating upregulated CXCR1 pre- and post-treatment.Conclusions Early irAE development post-ICB is associated with favourable survival in MM. Development of irAEs is coupled to expression of numerous gene pathways, suggesting irAE development in-part reflects baseline immune activation.Subject terms: Immunotherapy, Melanoma 相似文献
5.
Geneticists have, for years, understood the nature of genome‐wide association studies using common genomic variants. Recently, however, focus has shifted to the analysis of rare variants. This presents potential problems for researchers, as rare variants do not always behave in the same way common variants do, sometimes rendering decades of solid intuition moot. In this paper, we present examples of the differences between common and rare variants. We show why one must be significantly more careful about the origin of rare variants, and how failing to do so can lead to highly inflated type I error. We then explain how to best avoid such concerns with careful understanding and study design. Additionally, we demonstrate that a seemingly low error rate in next‐generation sequencing can dramatically impact the false‐positive rate for rare variants. This is due to the fact that rare variants are, by definition, seen infrequently, making it hard to distinguish between errors and real variants. Compounding this problem is the fact that the proportion of errors is likely to get worse, not better, with increasing sample size. One cannot simply scale their way up in order to solve this problem. Understanding these potential pitfalls is a key step in successfully identifying true associations between rare variants and diseases. 相似文献
6.
7.
ABSTRACTCommunication between health professionals and patients is an intergroup phenomenon where the health professional has the most power and status. Over the past few decades, there has been a steady increase in the availability to patients of information about healthcare and specific diseases on the Internet. In this paper, we ask whether the use of Internet health information assists patients to manage their consultations with health professionals better and whether it alters the intergroup dynamic by providing a more equal status for patients. In this study 370 participants from Australia and Canada completed a survey that included a ‘willingness to communicate with health professionals’ scale. They also commented on their use and trust of Internet health information. Thematic analysis suggests that patients’ use of Internet health information serves as a broker between patients and their health provider in health consultations. We discuss the implications of these findings for health practitioners as they address how easier Internet access influences patient interactions with health professionals. We consider future research directions these finding provide in explaining communication behaviour in this context. 相似文献
8.
Henry Havel Gregory Finch Pamela Strode Marc Wolfgang Stephen Zale Iulian Bobe Hagop Youssoufian Matthew Peterson Maggie Liu 《The AAPS journal》2016,18(6):1373-1378
Advancing nanomedicines from concept to clinic requires integration of new science with traditional pharmaceutical development. The medical and commercial success of nanomedicines is greatly facilitated when those charged with developing nanomedicines are cognizant of the unique opportunities and technical challenges that these products present. These individuals must also be knowledgeable about the processes of clinical and product development, including regulatory considerations, to maximize the odds for successful product registration. This article outlines these topics with a goal to accelerate the combination of academic innovation with collaborative industrial scientists who understand pharmaceutical development and regulatory approval requirements—only together can they realize the full potential of nanomedicines for patients. 相似文献
9.
PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease 下载免费PDF全文
10.